Diabetes and Endocrinology

Host: Jennifer Caudle, DO

Guest: Johanna Finkle, MD, FACOG

As GLP-1 therapies grow in popularity for weight management and diabetes, an unexpected consequence has emerged: a rise in unplanned pregnancies due to reduced oral contraceptive effectiveness. Dr. Jennifer Caudle sits down with Dr. Johanna Finkle, a weight loss specialist and OB/GYN at the University of Kansas Health System, to explore the mechanisms behind this trend and outline practical, long-acting contraceptive alternatives that maintain efficacy during GLP-1 use.

Host: Peter Buch, MD, FACG, AGAF, FACP

Guest: Michael Camilleri, MD

GLP-1 receptor agonists are revolutionizing treatment for diabetes and obesity, but their impact on the gastrointestinal tract demands careful clinical attention. Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine at the Mayo Foundation for Medical Education and Research in Rochester, Minnesota, to discuss key findings on gastrointestinal side effects, procedural risks, and the impacts of GLP-1 receptor agonists on the fields of gastroenterology and hepatology.

Host: Alejandro A. Rabinstein, MD, FAHA

Guest: Richard E. Pratley, MD

Guest: Jay H. Shubrook, DO, FACOFP, FAAFP

Listen to expert faculty discuss the role of GLP-1RAs in reducing stroke risk for patients with type 2 diabetes in this on-demand webcast with accompanying slides

Guest: Prof. Melanie Davies, MD

This educational program consists of 10 presentations on once-weekly basal insulin.

Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time.

Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland.

Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.

Host: Prof. Melanie Davies, MD

Guest: Athena Philis-Tsimikas, MD

This educational program consists of 10 presentations on once-weekly basal insulin.

Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time.

Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland.

Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.

Host: Athena Philis-Tsimikas, MD

This educational program consists of 10 presentations on once-weekly basal insulin.

Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time.

Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland.

Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.

Guest: Chantal Mathieu, MD, PhD

This educational program consists of 10 presentations on once-weekly basal insulin.

Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time.

Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland.

Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.

Host: Athena Philis-Tsimikas, MD

This educational program consists of 10 presentations on once-weekly basal insulin.

Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time.

Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland.

Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.

Host: Prof. Melanie Davies, MD

This educational program consists of 10 presentations on once-weekly basal insulin.

Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time.

Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland.

Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.

Host: Athena Philis-Tsimikas, MD

This educational program consists of 10 presentations on once-weekly basal insulin.

Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time.

Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland.

Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.